Skip to content

AOCI at other companies

Biogen logo
BiogenBIIB
-$140.2M+19.7%
Incyte logo
IncyteINCY
$22.31M+458%
AbbVie logo
AbbVieABBV
-$1.15B+33.8%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$270K-1,488%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$558K-328%
Nuvation Bio logo
Nuvation BioNUVB
-$1.68M-408%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.74B+95.0%
Enterprise value$1.96B+84.0%
P/S-12.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Syndax Pharmaceuticals's AOCI?
Syndax Pharmaceuticals (SNDX) reported AOCI of $11K in Q1 2026.
How has Syndax Pharmaceuticals's AOCI changed year-over-year?
Syndax Pharmaceuticals's AOCI decreased by 97.9% year-over-year, from $527K to $11K.
What is the long-term trend for Syndax Pharmaceuticals's AOCI?
Over 5 years (2020 to 2025), Syndax Pharmaceuticals's AOCI has grown at a 157.4% compound annual growth rate (CAGR), from -$4K to $452K.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.